The rationale behind it is that in a certain cancer microenvironment, IL-18 activates anti-tumor effector cells, such as T and NK cells, but the tumor uses IL-18’s natural antagonist, IL-18BP, to block this activity and thus evades the host’s immune system. The gene discussed is IL18; the disease is neoplasm.